Valneva SE (VALN) Other Working Capital Changes (2021 - 2026)
Valneva SE (VALN) posted Other Working Capital Changes of -$801960.8 for Q1 2026, down 4.57% sequentially from -$766900.1 in Q3 2025, and down 11.3% YoY from -$904125.5 in Q1 2025.
Analysis
Valneva SE (VALN) Other Working Capital Changes (2021 - 2026) Analysis & Trends
Valneva SE has reported Other Working Capital Changes for 6 years, with the latest figure at -$801960.8 in Q1 2026.
- Quarterly Other Working Capital Changes fell 11.3% year-over-year to -$801960.8 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$3.1 million (down 5.0% YoY) and the FY2024 annual result came in at -$2.9 million, up 13.0% from the prior year.
- Other Working Capital Changes eased to -$801960.8 in Q1 2026 per VALN's latest filing, from -$766900.1 in the prior quarter.
- Over five years, Other Working Capital Changes peaked at $1.9 billion in Q3 2023 and troughed at -$1.9 billion in Q2 2023.
- A 5-year average of -$825700.5 and a median of -$753718.7 in 2022 frame the typical range for Other Working Capital Changes.
- The widest YoY moves for Other Working Capital Changes: up 292306.32% in 2023, down 255621.4% in 2023.
- Over 5 years, Other Working Capital Changes stood at -$894756.9 in 2022, then increased by 17.87% to -$734867.0 in 2023, then soared by 110.03% to $73733.1 in 2024, then slumped by 1140.1% to -$766900.1 in 2025, then decreased by 4.57% to -$801960.8 in 2026.
- According to Business Quant data, Other Working Capital Changes over the past three periods registered -$801960.8, -$766900.1, and -$791239.8 for Q1 2026, Q3 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Valneva SE | 578.54 Mn | 437.28 Mn | 1.86 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 5.67 Mn |
| Jun 30, 2026 | 5.67 Mn |
| Mar 31, 2026 | 20.16 Mn |
| Mar 31, 2026 | 20.16 Mn |
| Dec 31, 2025 | -3.55 Mn |
| Dec 31, 2025 | -3.55 Mn |
| Sep 30, 2025 | 10.95 Mn |
| Sep 30, 2025 | 10.95 Mn |
| Jun 30, 2025 | 1.57 Mn |
| Jun 30, 2025 | 1.57 Mn |
| Mar 31, 2025 | -9.65 Mn |
| Mar 31, 2025 | -9.65 Mn |
| Dec 31, 2024 | 25.31 Mn |
| Dec 31, 2024 | 25.31 Mn |
| Sep 30, 2024 | -4.31 Mn |
| Sep 30, 2024 | -4.31 Mn |
| Jun 30, 2024 | -21.79 Mn |
| Jun 30, 2024 | -21.79 Mn |
| Mar 31, 2024 | -11.87 Mn |
| Mar 31, 2024 | -11.87 Mn |